Brahmi (Centella Asiatica / Gotu Kola) for Blood Circulation

Research suggests that Centella asiatica, particularly its standardized triterpenic fraction (TTFCA), has a relatively consistent body of evidence supporting its role in improving circulation-related outcomes, especially in conditions involving chronic venous insufficiency, venous hypertension, and diabetic microangiopathy. Studies indicate benefits across multiple measurable markers, including reductions in capillary fluid leakage, improvements in skin blood flow and oxygen levels, decreased ankle swelling, and faster healing of venous ulcers, with this evidence coming from a range of sources including multiple randomized controlled trials, several Cochrane meta-analyses, and a 2025 pilot study — nearly all pointing in a supportive direction. The proposed mechanisms, reviewed in both older and more recent literature, center on the plant's apparent ability to modulate collagen production and structural proteins in vein walls, as well as its anti-inflammatory and vascular-stabilizing properties. That said, individual trials are often small in scale, some studies rely on surrogate measures rather than hard clinical endpoints, and reviewers across multiple papers consistently call for larger and longer trials before stronger conclusions can be drawn.